注射用丹参多酚酸联合甲磺酸倍他司汀片治疗后循环缺血性眩晕的疗效
|
摘要
目的观察注射用丹参多酚酸联合甲磺酸倍他司汀片治疗后循环缺血性眩晕病人的临床疗效。方法将96例患者随机分为2组,各48例,对照组采取常规治疗,口服甲磺酸倍他司汀片,6 mg/次,3次/d,观察组加用注射用丹参多酚酸治疗,0.13 g加入到0.9%氯化钠注射液250 mL中静滴,1次/d,14 d后比较两组椎基底动脉供血和血流变指标、临床疗效和不良反应。结果观察组治疗后椎基底动脉血流速度(收缩期峰流速、舒张期末流速、平均流速)和血流变学指标(全血比黏度、血浆比黏度、纤维蛋白原)改善情况明显优于治疗前,且治疗后观察组优于对照组的,差异具有统计学意义(P<0.05);观察组痊愈率和总有效率均明显高于对照组,差异具有统计学意义(P<0.05),且两组均无不良反应发生。结论注射用丹参多酚酸联合甲磺酸倍他司汀片治疗椎后循环缺血性眩晕具良好的疗效,值得临床推广应用。
Objective To observe the clinical effect of Salvianolic Acids for Injection(SAFI) combined with Betahistine Mesilate Tablets(BMT) in the treatment of posterior circulation ischemic vertigo(PCIV). Methods In the 96 cases, patients with PCIV were randomly divided into observation group(n = 48) and control group(n = 48). Patients in the control group were given conventional therapy and oral BMT 6 mg tid, while the observation groups were treated by BMT combined with 0.13 g SAFI added for 250 mL0.9% sodium chloride intravenous drip qd. After all patients in the two groups treated for 14 d, the blood flow velocity of vertebrobasilar artery, hemorheological indexes, clinical efficacy, and adverse reactions of two groups were compared. Results After treatment, the blood flow velocity of vertebrobasilar artery(Vs, Vd, Vm), and hemorheological indexes(whole blood viscosity,plasma viscosity, fibrinogen) in the observation groups were significantly improved than those before treatment, the observation groups was significantly improved than control groups, and the difference was statistically significant(P < 0.05). The recovery rate and total efficiency of the observation groups were significantly higher than the control groups(P < 0.05), and there were no ADR patients in both groups. Conclusions SAFI combined with BMT in the treatment of PCIV has a good effect and is worthy of clinical application.
Objective To observe the clinical effect of Salvianolic Acids for Injection(SAFI) combined with Betahistine Mesilate Tablets(BMT) in the treatment of posterior circulation ischemic vertigo(PCIV). Methods In the 96 cases, patients with PCIV were randomly divided into observation group(n = 48) and control group(n = 48). Patients in the control group were given conventional therapy and oral BMT 6 mg tid, while the observation groups were treated by BMT combined with 0.13 g SAFI added for 250 mL0.9% sodium chloride intravenous drip qd. After all patients in the two groups treated for 14 d, the blood flow velocity of vertebrobasilar artery, hemorheological indexes, clinical efficacy, and adverse reactions of two groups were compared. Results After treatment, the blood flow velocity of vertebrobasilar artery(Vs, Vd, Vm), and hemorheological indexes(whole blood viscosity,plasma viscosity, fibrinogen) in the observation groups were significantly improved than those before treatment, the observation groups was significantly improved than control groups, and the difference was statistically significant(P < 0.05). The recovery rate and total efficiency of the observation groups were significantly higher than the control groups(P < 0.05), and there were no ADR patients in both groups. Conclusions SAFI combined with BMT in the treatment of PCIV has a good effect and is worthy of clinical application.
引文
[1]陈婉兰.活血补气祛痰汤治疗椎基底动脉供血不足性眩晕对照研究[J].中国实用神经疾病杂志, 2017, 20(2):93-95.
[2]高磊. 42例神经内科眩晕症患者临床分析[J].中国实用神经疾病杂志, 2017, 20(5):85-86.
[3]张慧杰,任晓亮,崔明磊,等.注射用丹参多酚酸中主要成分的降解动力学分析[J].中国实验方剂学杂志,2013, 19(14):1-5.
[4]刘君动,叶正良,李德坤,等.近红外漫反射光谱法快速测定注射用丹参多酚酸中的水分[J].中国实验方剂学杂志, 2012, 18(4):91-94.
[5]周凤,邓幼清,陈小红,等.注射用丹参多酚酸治疗脑梗死恢复期(瘀血阻络型)临床研究[J].实用中西医结合临床, 2013, 13(8):8-13.
[6]张玉霞.注射用丹参多酚酸辅治脑梗塞疗效观察[J].中医临床研究, 2014, 6(4):91-92.
[7]侯熙簿.神经病学[M].第3版.北京:人民卫生出版社,1996:111.
[8]国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社, 2012:20-21.
[9]中华人民共和国卫生部.中药新药临床研究指导原则[S].中国中医药出版社, 1993:24-26.
[10]邓燕.长春西汀治疗慢性脑供血不足的疗效观察[J].中国实用神经疾病杂志, 2016, 19(14):20-22.
[11]田介峰,阎红,王瑞静,等.丹参多酚酸提取物化学成分的分离与鉴定[J].中草药, 2018,4 9(21):5024-5028.
[12]许磊,温时媛,王跃飞,等. NMR法同时测定注射用丹参多酚酸中的迷迭香酸、紫草酸、丹酚酸B和甘露醇[J].中成药, 2015, 37(10):2185-2189.
[13]薛静,叶正良,李德坤,等.注射用丹参多酚酸中鞣质类物质的排除性检测[J].中国实验方剂学杂志, 2013,19(4):93-95.
[14]刘君动,叶正良,李德坤,等.超滤法应用于注射用丹参多酚酸制剂工艺中的研究[J].陕西中医, 2012, 33(2):231-233.
[15]孙丽霞.注射用丹参多酚酸治疗进展性脑梗死效果观察[J].中国医药, 2015, 10(6):816-818.
[16]孙莉,雷德宝.注射用丹参多酚酸对缺血性脑卒中患者的安全性评价[J].襄阳职业技术学院学报, 2013, 12(6):18-20.
[17]何前松,马萌萌,胡利民,等.丹参多酚酸对大鼠糖尿病脑缺血再灌注损伤恢复期相关基因表达的影响[J].中国实验方剂学杂志, 2015, 21(7):80-86.
[18]史国玉,周凤琴,郭庆梅.丹参与白花丹参叶化学成分与药理临床研究进展[J].时珍国医国药, 2011, 22(2):465-467.
[19]郝彦超,苏建.丹参多酚酸对脑梗死患者血液流变学和神经功能的影响[J].中国实用神经疾病杂志, 2014,17(16):67-68.
[2]高磊. 42例神经内科眩晕症患者临床分析[J].中国实用神经疾病杂志, 2017, 20(5):85-86.
[3]张慧杰,任晓亮,崔明磊,等.注射用丹参多酚酸中主要成分的降解动力学分析[J].中国实验方剂学杂志,2013, 19(14):1-5.
[4]刘君动,叶正良,李德坤,等.近红外漫反射光谱法快速测定注射用丹参多酚酸中的水分[J].中国实验方剂学杂志, 2012, 18(4):91-94.
[5]周凤,邓幼清,陈小红,等.注射用丹参多酚酸治疗脑梗死恢复期(瘀血阻络型)临床研究[J].实用中西医结合临床, 2013, 13(8):8-13.
[6]张玉霞.注射用丹参多酚酸辅治脑梗塞疗效观察[J].中医临床研究, 2014, 6(4):91-92.
[7]侯熙簿.神经病学[M].第3版.北京:人民卫生出版社,1996:111.
[8]国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社, 2012:20-21.
[9]中华人民共和国卫生部.中药新药临床研究指导原则[S].中国中医药出版社, 1993:24-26.
[10]邓燕.长春西汀治疗慢性脑供血不足的疗效观察[J].中国实用神经疾病杂志, 2016, 19(14):20-22.
[11]田介峰,阎红,王瑞静,等.丹参多酚酸提取物化学成分的分离与鉴定[J].中草药, 2018,4 9(21):5024-5028.
[12]许磊,温时媛,王跃飞,等. NMR法同时测定注射用丹参多酚酸中的迷迭香酸、紫草酸、丹酚酸B和甘露醇[J].中成药, 2015, 37(10):2185-2189.
[13]薛静,叶正良,李德坤,等.注射用丹参多酚酸中鞣质类物质的排除性检测[J].中国实验方剂学杂志, 2013,19(4):93-95.
[14]刘君动,叶正良,李德坤,等.超滤法应用于注射用丹参多酚酸制剂工艺中的研究[J].陕西中医, 2012, 33(2):231-233.
[15]孙丽霞.注射用丹参多酚酸治疗进展性脑梗死效果观察[J].中国医药, 2015, 10(6):816-818.
[16]孙莉,雷德宝.注射用丹参多酚酸对缺血性脑卒中患者的安全性评价[J].襄阳职业技术学院学报, 2013, 12(6):18-20.
[17]何前松,马萌萌,胡利民,等.丹参多酚酸对大鼠糖尿病脑缺血再灌注损伤恢复期相关基因表达的影响[J].中国实验方剂学杂志, 2015, 21(7):80-86.
[18]史国玉,周凤琴,郭庆梅.丹参与白花丹参叶化学成分与药理临床研究进展[J].时珍国医国药, 2011, 22(2):465-467.
[19]郝彦超,苏建.丹参多酚酸对脑梗死患者血液流变学和神经功能的影响[J].中国实用神经疾病杂志, 2014,17(16):67-68.